ArticleCancer immunology, immunotherapy : CII2025
Integrative analysis of single-cell and bulk transcriptome data reveals age-related immune cell alterations in primary glioblastoma associated with prognosis.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is the most malignant and highly recurrent brain tumor. Although over half of the GBM patients are elderly patients, the understanding of how aging affects GBM progression remains limited.
methodsClinical and genomic variation data of GBM patients from TCGA and CGGA databases were used for prognostic analysis. We collected single-cell transcriptome data of 88,908 cells from 13 primary GBM (pGBM) and 12 recurrent GBM (rGBM) patients. Age-related immune cells were identified through cell-cell communication and trajectory analysis. The results were validated by projecting the single-cell transcriptome profiles onto bulk data. Finally, we experimentally validated the results on syngeneic orthotopic models of younger and older mice.
resultsPrognostic analysis indicated the effect of age in pGBM patients is stronger than that in rGBM patients. Moreover, the mutational signatures in pGBM does not affect prognosis. Single-cell RNA sequencing analysis revealed age-related differences in immune cells between pGBM and rGBM, and identified microglia underwent significant cell state changes with aging only in pGBM patients. Next, we validated that high expression of HSPB1 in microglia from older pGBM patients is associated with poor prognosis. Finally, the syngeneic orthotopic model for aged mice exhibited more tumor invasion, with a shorter median survival time. Furthermore, the microglia within the tumor microenvironment (TME) of aged mice showed markedly high expression level of HSPB1.
conclusionsOur study highlights the crucial role of microglial aging in pGBM, reveals distinct age-related changes of immune cells in the TME between pGBM and rGBM, and offers valuable insights into clinical treatment strategies targeting elderly GBM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.